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In recent years the physiological role of the proin-
sulin C-peptide has received increasing attention,
focusing on the potential therapeutic value of
C-peptide replacement in preventing and ameliorat-
ing type I diabetic complications. In order to consol-
idate these new data and to identify the immediate
directions of C-peptide research and its clinical
usefulness, an International Symposium was held
in Detroit, Michigan, on October 20-21, 2000, under
the auspices of the Wayne State University/Morris
Hood Jr. Comprehensive Diabetes Center. In this
communication, we review the cellular, physiologi-
cal and clinical effects of C-peptide replacement in
animal models and in patients with type 1 diabetes.
Finally, recommendations ae presented as to the
most urgent studies that should be pursued to fur-
ther establish the biological action of C-peptide and
its therapeutic value.
facilitated. [1,2] C-peptide is subsequently cleaved
from the proinsulin molecule and released to the
circulation in amounts equimolar to insulin. Fol-
lowing discovery of the mode of insulin synthe-
sis, several early studies addressed the question
of possible insulin-like effects of C-peptide.
None were found and it became generally
accepted that C-peptide had no other role than
its participation in insulin biosynthesis. Howev-
er, recent reports of cellular binding interactions
of C-peptide TM and the finding of physiological
effects in patients with type 1 diabetes, who are
C-peptide deficient, have prompted renewed
interest in this peptide. [4]
INTRODUCTION
C-peptide fulfills an important function in the
biosynthesis of insulin by bringing its A and B
chains together. The process of folding and
disulfide bond formation, necessary for the
generation of bioactive insulin, is thereby
The C-peptide Molecule
The species variability of the C-peptide molecule
is greater than for the surroundingA and B chains
of insulin, and for many bioactive peptides, but
other hormones, like parathyroid hormone and
gastrin-releasing peptide, also show considerable
inter-species variability. The largely conserved
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mammalian sequence pattern of C-peptides
includes four non-consecutive positions with
glutamic acid, an interspaced glycine-rich
segment, and some further residues. As a result,
the C-peptide residue pattern provides a basis for
ligand-receptor binding interactions. Their nature
is yet unknown, but spacing is obviously impor-
tant, in a manner like that seen for the major histo-
compatibility molecules, in which the residue
spacing provides sites of defined interactions. [5,6]
Cellular Interactions
Measurements using fluorescence correlation
spectroscopy have established the occurrence of
C-peptide cell membrane interactions. [31 There
is now direct evidence for a stereospecific bind-
ing of C-peptide in the nanomolar concentration
range to surfaces of several cell types, e.g., renal
tubular cells, fibroblasts and endothelial cells.
The specificity of the binding is demonstrated by
competitive displacement of bound C-peptide
by excess concentration of native C-peptide and
by the inability of both scrambled C-peptide (the
same amino acid residues as C-peptide but ran-
domly assembled) and D-C-peptide to displace
binding. The COOH-terminal pentapeptide seg-
ment is essential for C-peptide binding and may
constitute an active site of the molecule. [3] The
binding probably involves a G-protein, since
pretreatment of celJ[s with pertussis toxin results
in loss of binding. The affinity binding constant
for C-peptide is of the order of 3.109 M-1 and
saturation of binding occurs at physiological
concentrations (-0.9nM). This finding helps
explain why no effects of C-peptide have been
observed in healthy subjects or animals-binding
site saturation is reached already at physiologi-
cal C-peptide concentrations. Thus, additional
effects cannot be expected from further increases
in C-peptide concentrations. C-peptide binding
is not displaced by molar excess of insulin,
proinsulin, IGF-I, IGF-II, or NPY, nor is
insulin bound to cell membranes displaced by
C-peptide. However, it cannot be excluded that
C-peptide binds to e.g., the insulin receptor, but
at a different site than that for insulin itself.
Indeed, recent studies suggest a possible inter-
action between C-peptide and insulin. Data from
studies in isolated human skeletal muscle strips
indicate that C-peptide stimulates glucose trans-
port, but via a mechanism that is independent of
the insulin receptor and of tyrosine kinase acti-
vation. [7] On the other hand, in rat L6 myoblasts,
physiological concentrations of C-peptide has
been shown to autophosphorylate the insulin
receptor, stimulate tyrosine kinase, IRS-1 tyro-
sine phosphorylation, P13 kinase activity, MAPK
phosphorylation, p 90 Rsk and GSK-3 phospho-
rylation. [81 These effects result in glycogen syn-
thesis and amino acid uptake. Similar effects
cannot be demonstrated by scrambled C-pep-
tide. The data suggest the possibility that the
insulin signaling pathway may be activated by
both C-peptide and insulin. [81
A short term effect of C-peptide on glucose
utilization has been demonstrated in type 1
patients with the euglycemic clamp technique.
These studies demonstrate a 25% increase when
C-peptide was acutely raised to physiological
lex;els, whereas further increases had no addi-
tional effect. [91 These findings correlate with
measurements of increased glucose uptake
by resting and exercising forearm muscle during
C-peptide infusion.[1] and increased glucose
uptake by muscle-strips from diabetic sub-
jects. [11] However, in patients receiving C-pep-
tide plus insulin for 3 months, blood glucose
levels, indices of metabolic control, and insulin
doses, were all unchanged as compared to non
C-peptide treated controls. [7]
The effects of C-peptide concerning two of
the characteristic abnormalities in type 1 dia-
betes, i.e., impaired Na+, K+-ATPase activity
and reduced endothelial function are probably
more important than the C-peptide influence
on glucose utilization. A first outline of an
intracellular signal transduction pattern now
emerges. Exposure of cells to C-peptide
in physiological concentrations results in
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activation of a G-protein, a rise in intracellular
Ca2+-concentration from extracellular sources
and subsequent activation of Ca2+-dependent
protein phosphatase IIB, leading to conversion
of inactive phosphorylated Na+, K+-ATPase to
its active dephosphorylated form. [12] The
COOH-terminal pentapeptide is as effective as
the intact C-peptide molecule in stimulating
Na+, K+-ATPase activity. [13] In addition, in
endothelial cells the rise in Ca2+ -concentration
is accompanied by augmented activity of
endothelial nitric oxide synthase (eNOS). [14]
Furthermore, several findings suggest that
C-peptide may interact with other hormones
and growth factors. The effect of C-peptide on
Na+,K+-ATPase is potentiated by the presence
of sub-threshold concentrations of neuropep-
tide y.[12]
Physiological Effects
C-peptide has been found to elicit concentration-
dependent stimulation of Na+, K+ -ATPase activi-
ty in a variety of tissues including renal tubular
cells, [12] rat sciatic nerve, [5,16] pancreatic islets, [17.]
granulation tissue [161 and red blood cells. [14,18]
C-peptide exerts an ameliorating effect on the
impaired deformability of red blood cells from
type I diabetic patients, which is probably mediat-
ed via its effects on Na+, K+ -ATPase. Further sup-
port for the C-peptide effects on Na+, K+ -ATPase
is provided by its effect on rat sciatic nerve
Na+, K+-ATPase in type 1 diabetic BB/Wor-rats
treated with C-peptide for 8 months.[15,191 This
effect is further substantiated by partial correction
of the Na+, K+ -ATPase associated defect in nerve
conduction velocity and paranodal swelling, sec-
ondary to axonal Na+ accumulation. [19] Further-
more, "m the C-peptide deficient diabetic
BB/Wor-rat model the expression of both the
insulin receptor and the IGF-I receptor mRNA
and protein in peripheral nerve and brain tissue
were normalized by C-peptide replacement, [2,21]
and the diabetes-induced hippocampal apoptosis
was prevented by C-peptide replacement. [21]
In type 1 diabetic patients, autonomic nerve
function as measured by heart rate variability
during deep breathing improves after intra-
venous C-peptide infusion for 3h,[22] and in
months. patients who receive C-peptide for 3 [7]
A subgroup of the latter patients with signs of
sensory neuropathy exhibits improved tempera-
ture threshold discrimination after C-peptide
montts. None of these replacement for 3 [7]
effects are seen in patients who receive insulin
therapy alone. There is no immediate explana-
tion for the beneficial effects of C-peptide on
nerve function and structure. It may be related
to a stimulation of nerve Na+, K+ -ATPase activ-
ity, resulting in improved electrolyte balance and
enzyme state. Alternatively, the effects may be a
consequence of improved neural blood flow.
Several studies demonstrate an effect of C-pep-
tide on NO-release. It stimulates eNOS, causing
release of NO from bovine aortic endothelial
cells in a concentration-dependent manner,
an effect that is abolished by NO-synthase
inhibitors. [23] This is in keeping with the finding
that C-peptide induces an increase in forearm
blood flow in type 1 diabetic patients, which is
blocked by a NO-synthase blocker. [24] It is also
consistent with the demonstration of a C-pep-
tide concentration-dependent dilatation of rat
skeletal muscle arterioles in the presence of
insulin.J251
C-peptide replacement in streptozotocin diabet-
ic rats extending from 120min to 14 days results in
diminished glomerular hyperfiltration, increased
functional reserve and reduced urinary albumin
extraction.[26,27] In addition, the renal weight tends
to be lower and the glomerular volume was signif-
icantly smaller in C-peptide treated animals then
in non-treated controls.[27] These data have been
confirmed in clinical studies in patients with type
1 diabetes. Thus, C-peptide replacement during
3h and during 1 month in young patients with
early signs of diabetic nephropathy, i.e., glomeru-
lar hyperfiltration but absence of manifest micro-
albuminuria, was accompanied by reduced
glomerular hyperfiltration and decreased filtration
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fraction. [9’28] Furthermore, in a double-blind,
randomized, cross-over stud) C-peptide replace-
ment for 3 months in patients with microalbumin-
uria resulted in a 40% reduction in urinary
albumin excretion. [7] It may be hypothesized that
C-pepfide has the potential, via stimulation of
Na+, K+-ATPase, to influence membrane perme-
ability of the nephron and to normalize regional
blood flow, resulting of improvements in renal
function in the diabetic state.
Little information is available regarding the
possible influence of C-peptide on retinopathy
in type 1 diabetes. However, one study demon-
strates diminished leakage of fluorescein across
the blood-retinal barrier after 4 weeks of C-pep-
tide replacement in young type 1 patients, [24] an
effect possibly related to the ability of C-peptide
to stimulate blood flow and increase capillary
recruitment.[29]
Summary
Experimental and clinical data now convincingly
demonstrate that C-peptide exerts biological
effects of its own. The effects are concentration-
dependent, in the low physiological range,
and most likely mediated via stimulation of Na+,
K+-ATPase and eNOS activities. Animal and
human data indicate that C-peptide has a preven-
tive and ameliorating effect on the chronic compli-
cations in type 1 diabetes particularly as regards
diabetic neuropathy and nephropathy. However,
its mode of receptor interaction, signaling path-
ways and potential interaction with insulin or
other hormones are still incompletely understood.
Therefore, based on the deliberations at this con-
sensus meeting, the C-peptide study group agreed
on the following recommendations:
Recommendations
1. Efforts should be directed to identify and
characterize the C-peptide receptor and to
explore as to whether C-peptide interacts
with other receptors.
2. Further work will be needed to identify sig-
naling pathways utilized by C-peptide.
3. Interactions with other hormones, growth
factors and transcription factors need to be
explored.
4. Elucidation of the effect of C-peptide on
blood flow in the target tissues of diabetic
complications should be persued.
5. The anti-apoptotic effect of C-peptide
should be examined in different tissues and
cell systems.
6. Examination of the effects of C-peptide on
free radical formation and scavenging in
tissues of diabetic complications should be
performed
7. Clinical trials should be conducted with
respect to diabetic neuropathy and
nephropathy.
8. The effect of C-peptide replacement on
the development of diabetic retinopathy
should be examined in appropriate animal
models.
9. Appropriate delivery systems should be
designed for convenient and continuous
administration of C-peptide.
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